DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Medicare & Medicaid Services 7500 Security Boulevard, Mail Stop S3-02-01 Baltimore, Maryland 21244-1850



August 23, 2022

Carl Schmid
Executive Director
HIV+Hepatitis Policy Institute
1602 Belmont St NW #B
Washington, DC 20009
cschmid@hivhep.org

Dear Mr. Schmid:

Thank you for your letter on behalf of human immunodeficiency virus (HIV) community-based organizations, advocacy groups, providers, public health practitioners, and people living with and at increased risk for HIV. The information that you provided will be particularly helpful when we begin to analyze a coverage policy for Pre-Exposure Prophylaxis (PrEP) for HIV Prevention.

We recognize the importance of PrEP and its substantial benefit for decreasing the risk of HIV infection in persons at high risk of HIV infection, either via sexual acquisition or through injection drug use. We also understand the need for Medicare beneficiaries to have access to the newest improvements in HIV prevention, diagnosis, and treatment. The United State Preventive Services Task Force (USPSTF) is reviewing new evidence, including public comments, to issue a final recommendation for PrEP. The Centers for Medicare & Medicaid Services is closely following the USPSTF progress on this topic as their final recommendation is required for determining Medicare coverage. While we do not have further information to share regarding the timeline of a National Coverage Analysis on PrEP, we look forward to engaging with you and other stakeholders.

Thank you again for your letter and raising these important issues. If you have further thoughts or questions, please have your staff contact Rachel Katonak at rachel.katonak@cms.hhs.gov. Please share this response with your co-signers.

Sincerely,

Lee A. Fleisher, MD

Chief Medical Officer and Director

u 1.70

Center for Clinical Standards and Quality Centers for Medicare & Medicaid Services